Ultrasound common hepatic artery denervation (CHA-D) as a novel neuromodulatory strategy for cardiovascular-kidney-metabolic syndrome: first-in-human experience - Takeaways - MDSpire

Ultrasound common hepatic artery denervation (CHA-D) as a novel neuromodulatory strategy for cardiovascular-kidney-metabolic syndrome: first-in-human experience

  • By

  • Mert Tokcan

  • Franciska Diana Wolter

  • Mathias Hohl

  • Peter Fries

  • Thorsten Kessler

  • Saarraaken Kulenthiran

  • Michael Böhm

  • June 3, 2026

  • 0 min

Share

  • 1

    Ultrasound-guided common hepatic artery denervation (CHA-D) is explored as a novel treatment for uncontrolled hypertension and cardiometabolic syndrome.

  • 2

    The procedure was performed on a patient with severe hypertension unresponsive to standard treatments, highlighting its potential as an alternative.

  • 3

    Pre-procedural assessments included imaging and laboratory tests to ensure patient safety and eligibility for CHA-D.

  • 4

    The intervention involved selective catheterization and ultrasound ablation of the common hepatic artery, monitored for safety throughout.

  • 5

    Initial findings suggest that CHA-D may enhance blood pressure reduction and improve metabolic parameters in patients with resistant hypertension.

Original Source(s)

Ultrasound common hepatic artery denervation (CHA-D) as a novel neuromodulatory strategy for cardiovascular-kidney-metabolic syndrome: first-in-human experience

  • by Mert Tokcan, Franciska Diana Wolter, Mathias Hohl, Peter Fries, Thorsten Kessler, Saarraaken Kulenthiran, Michael Böhm

  • June 3, 2026

Related Content

Does Weight Loss Intervention Improve Persistent AF?

Randomized trial found significant weight loss did not improve atrial fibrillation severity or burden in older patients with persistent disease.

Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.